en
Scientific article
Review
English

How developing world concerns need to be part of drug development plans: a case study of four emerging antiretrovirals

Published inDrug discovery today, vol. 13, no. 13-14, p. 601-605
Publication date2008-07
First online date2008-06-17
Abstract

Clinical trials are usually designed to meet registration requirements in developed countries, and do not always address key concerns for use in developing countries. Four late-stage investigational new drugs - rilpivirine, etravirine, raltegravir and maraviroc - show potential to improve antiretroviral therapy. However, a number of issues could limit their use in developing countries, including dose selection, treatment strategy, combination with other drugs, use in specific populations and reliance on expensive tests. Key research questions relevant for developing countries need to be answered early in the drug development process to ensure maximum benefit for the majority.

eng
Keywords
  • Anti-Retroviral Agents / administration & dosage
  • Anti-Retroviral Agents / therapeutic use
  • Developing Countries
  • Dose-Response Relationship, Drug
  • Drug Design
  • Humans
  • Retroviridae Infections / drug therapy
  • Retroviridae Infections / epidemiology
  • Retroviridae Infections / virology
Research group
Citation (ISO format)
VAN ROEY, Jens et al. How developing world concerns need to be part of drug development plans: a case study of four emerging antiretrovirals. In: Drug discovery today, 2008, vol. 13, n° 13-14, p. 601–605. doi: 10.1016/j.drudis.2008.04.009
Main files (1)
Article (Published version)
accessLevelRestricted
Identifiers
ISSN of the journal1359-6446
21views
0downloads

Technical informations

Creation02/07/2023 8:48:24 AM
First validation11/20/2023 3:08:38 PM
Update time11/20/2023 3:08:38 PM
Status update11/20/2023 3:08:38 PM
Last indexation05/06/2024 5:25:47 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack